Correction to: Scientific Reports https://doi.org/10.1038/s41598-018-26442-0, published online 23 May 2018

The Article contains errors in the Reference list. The order of References 28 – 35 is incorrect. The correct order of References 28-35 appears below.

28) Saed, G. M., Collins, K. L. & Diamond, M. P. Transforming growth factors beta1, beta2 and beta3 and their receptors are differentially expressed in human peritoneal fibroblasts in response to hypoxia. Am. J. Reprod. Immunol. 48(6), 387-93 (2002).

29) Yafai, Y. et al. Müller glial cells inhibit proliferation of retinal endothelial cells via TGF-β2 and Smad signaling. Glia 62(9), 1476-85 (2014).

30) López-Casillas, F., Payne, H. M., Andres, J. L. & Massagué, J. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J. Cell. Biol. 124(4), 557-68 (1994).

31) Sankar, S., Mahooti-Brooks, N., Centrella, M., McCarthy, T. L. & Madri, J. A. Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2. J. Biol. Chem. 270(22), 13567-72 (1995).

32) Yamashita, H. et al. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. J. Biol. Chem. 269(3), 1995-2001 (1994).

33) Yamauchi, K. et al. Vascular endothelial cell growth factor attenuates actions of transforming growth factor-beta in human endothelial cells. J. Biol. Chem. 279(53), 55104-8 (2004).

34) Galvagni, F. et al. CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration adhesion and migration. Oncotarget 7(9), 10090-103 (2016).

35) Tosi, G. M. et al. CD93 as a Potential Target in Neovascular Age-Related Macular Degeneration. J. Cell. Physiol. 232(7), 1767-1773 (2017).